Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 4 Issue 12, December 2023

2023 in Review

This month we present a dedicated Focus issue, ‘2023 in Review’, that includes news, analyses and comments on the advances and challenges of the past year, together with highlights from the primary research articles published in Nature Cancer and elsewhere over the past 12 months.

See our December Editorial and associated Focus content.

Image: ICP-Tech / Incamerastock / Alamy Stock Photo. Cover design: Allen Beattie

Volume 4 Issue 12

Subscribe

Editorial

  • We bid farewell to the past year with a set of specially commissioned commentaries, news articles and a selection of highlights from the cancer research literature.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

Comment & Opinion

  • Neoantigen immunogenicity prediction is a burgeoning field with vast potential; however, the shortage of high-quality data and biases in current datasets limit model generalizability. Here we discuss some of the pitfalls that may underly this limited performance and propose a path forward.

    • Hugh O’Brien
    • Max Salm
    • Sergio A. Quezada
    Comment

  • Owing to high response rates, the Food and Drug Administration has approved both gene- and immune-targeted drugs for tumor-agnostic, genomic biomarker-based indications, for lethal solid and blood cancers. We posit that current data support tissue-agnostic activity as a paradigm, rather than an exception to the rule.

    • Jacob J. Adashek
    • Shumei Kato
    • Razelle Kurzrock
    Comment

  • Real-world data (RWD) and real-world evidence (RWE) from heterogeneous data sources has the potential to transform oncology research, especially when coupled with artificial intelligence (AI). We discuss the issues involved in primary data capture and post-hoc AI analysis and propose using AI to support the capture of primary RWD.

    • Piers Mahon
    • Geoff Hall
    • Giovanni Tonon
    Comment

  • Twelve early-career investigators share their thoughts on the experiences they had starting their laboratories in 2023 and reflect on the opportunities they seized and the challenges they faced.

    • Joanna Achinger-Kawecka
    • Santiago Correa
    • Caroline J. Watson
    Viewpoint
Top of page ⤴

Research Highlights

Top of page ⤴

Research

Top of page ⤴

Search

Advanced search

Quick links